The role of ¹²³I imaging in the evaluation of infants with mild congenital hypothyroidism

Evan Graber, Molly O. Regelmann, Rachel Annunziato, Josef Machac, Robert Rapaport

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Controversy exists regarding the diagnosis and treatment of mild congenital hypothyroidism (MCH). We studied the value of (123)I imaging in patients with MCH.

METHODS: Retrospective chart review of infants and children <4 years of age who underwent (123)I imaging: group 1 = MCH [thyroid-stimulating hormone (TSH) <25 µIU/ml, normal free T4/T3], group 2 = severe congenital hypothyroidism (TSH ≥25 µIU/ml), and group 3 = MCH in infancy imaged after treatment withdrawal at age 3 years. Data collected included 4- and 24-hour (123)I uptake, TSH, free T4/total T3 at imaging, age at imaging, and levothyroxine (L-T4) dose at 1 year of.

RESULTS: Thirty-six patients underwent (123)I imaging. In group 1 (n = 20, median TSH: 8.49 µIU/ml), 85% had abnormal imaging consistent with dyshormonogenesis. Two patients were referred after 1 year of age. The median age at imaging for the remaining 18 patients was 54 days. Median L-T4 dose at 1 year of age for these 18 patients was 2.8 μg/kg, which is consistent with dyshormonogenesis. Ninety-one percent of group 2 (n = 11, median TSH: 428.03 µIU/ml) had abnormal imaging. The median age at imaging was 13 days. Four patients in group 3 had abnormal (123)I imaging and restarted treatment.

CONCLUSION: (123)I imaging is a valuable tool for evaluation, diagnosis, and treatment of MCH.

Original languageEnglish (US)
Pages (from-to)94-101
Number of pages8
JournalHormone research in pædiatrics
Volume83
Issue number2
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Congenital Hypothyroidism
Thyrotropin
Therapeutics
Thyroxine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The role of ¹²³I imaging in the evaluation of infants with mild congenital hypothyroidism. / Graber, Evan; Regelmann, Molly O.; Annunziato, Rachel; Machac, Josef; Rapaport, Robert.

In: Hormone research in pædiatrics, Vol. 83, No. 2, 2015, p. 94-101.

Research output: Contribution to journalArticle

Graber, Evan ; Regelmann, Molly O. ; Annunziato, Rachel ; Machac, Josef ; Rapaport, Robert. / The role of ¹²³I imaging in the evaluation of infants with mild congenital hypothyroidism. In: Hormone research in pædiatrics. 2015 ; Vol. 83, No. 2. pp. 94-101.
@article{258ebaf4fafd4108b51be01e7272596d,
title = "The role of ¹²³I imaging in the evaluation of infants with mild congenital hypothyroidism",
abstract = "BACKGROUND/AIMS: Controversy exists regarding the diagnosis and treatment of mild congenital hypothyroidism (MCH). We studied the value of (123)I imaging in patients with MCH.METHODS: Retrospective chart review of infants and children <4 years of age who underwent (123)I imaging: group 1 = MCH [thyroid-stimulating hormone (TSH) <25 µIU/ml, normal free T4/T3], group 2 = severe congenital hypothyroidism (TSH ≥25 µIU/ml), and group 3 = MCH in infancy imaged after treatment withdrawal at age 3 years. Data collected included 4- and 24-hour (123)I uptake, TSH, free T4/total T3 at imaging, age at imaging, and levothyroxine (L-T4) dose at 1 year of.RESULTS: Thirty-six patients underwent (123)I imaging. In group 1 (n = 20, median TSH: 8.49 µIU/ml), 85{\%} had abnormal imaging consistent with dyshormonogenesis. Two patients were referred after 1 year of age. The median age at imaging for the remaining 18 patients was 54 days. Median L-T4 dose at 1 year of age for these 18 patients was 2.8 μg/kg, which is consistent with dyshormonogenesis. Ninety-one percent of group 2 (n = 11, median TSH: 428.03 µIU/ml) had abnormal imaging. The median age at imaging was 13 days. Four patients in group 3 had abnormal (123)I imaging and restarted treatment.CONCLUSION: (123)I imaging is a valuable tool for evaluation, diagnosis, and treatment of MCH.",
author = "Evan Graber and Regelmann, {Molly O.} and Rachel Annunziato and Josef Machac and Robert Rapaport",
year = "2015",
doi = "10.1159/000367992",
language = "English (US)",
volume = "83",
pages = "94--101",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - The role of ¹²³I imaging in the evaluation of infants with mild congenital hypothyroidism

AU - Graber, Evan

AU - Regelmann, Molly O.

AU - Annunziato, Rachel

AU - Machac, Josef

AU - Rapaport, Robert

PY - 2015

Y1 - 2015

N2 - BACKGROUND/AIMS: Controversy exists regarding the diagnosis and treatment of mild congenital hypothyroidism (MCH). We studied the value of (123)I imaging in patients with MCH.METHODS: Retrospective chart review of infants and children <4 years of age who underwent (123)I imaging: group 1 = MCH [thyroid-stimulating hormone (TSH) <25 µIU/ml, normal free T4/T3], group 2 = severe congenital hypothyroidism (TSH ≥25 µIU/ml), and group 3 = MCH in infancy imaged after treatment withdrawal at age 3 years. Data collected included 4- and 24-hour (123)I uptake, TSH, free T4/total T3 at imaging, age at imaging, and levothyroxine (L-T4) dose at 1 year of.RESULTS: Thirty-six patients underwent (123)I imaging. In group 1 (n = 20, median TSH: 8.49 µIU/ml), 85% had abnormal imaging consistent with dyshormonogenesis. Two patients were referred after 1 year of age. The median age at imaging for the remaining 18 patients was 54 days. Median L-T4 dose at 1 year of age for these 18 patients was 2.8 μg/kg, which is consistent with dyshormonogenesis. Ninety-one percent of group 2 (n = 11, median TSH: 428.03 µIU/ml) had abnormal imaging. The median age at imaging was 13 days. Four patients in group 3 had abnormal (123)I imaging and restarted treatment.CONCLUSION: (123)I imaging is a valuable tool for evaluation, diagnosis, and treatment of MCH.

AB - BACKGROUND/AIMS: Controversy exists regarding the diagnosis and treatment of mild congenital hypothyroidism (MCH). We studied the value of (123)I imaging in patients with MCH.METHODS: Retrospective chart review of infants and children <4 years of age who underwent (123)I imaging: group 1 = MCH [thyroid-stimulating hormone (TSH) <25 µIU/ml, normal free T4/T3], group 2 = severe congenital hypothyroidism (TSH ≥25 µIU/ml), and group 3 = MCH in infancy imaged after treatment withdrawal at age 3 years. Data collected included 4- and 24-hour (123)I uptake, TSH, free T4/total T3 at imaging, age at imaging, and levothyroxine (L-T4) dose at 1 year of.RESULTS: Thirty-six patients underwent (123)I imaging. In group 1 (n = 20, median TSH: 8.49 µIU/ml), 85% had abnormal imaging consistent with dyshormonogenesis. Two patients were referred after 1 year of age. The median age at imaging for the remaining 18 patients was 54 days. Median L-T4 dose at 1 year of age for these 18 patients was 2.8 μg/kg, which is consistent with dyshormonogenesis. Ninety-one percent of group 2 (n = 11, median TSH: 428.03 µIU/ml) had abnormal imaging. The median age at imaging was 13 days. Four patients in group 3 had abnormal (123)I imaging and restarted treatment.CONCLUSION: (123)I imaging is a valuable tool for evaluation, diagnosis, and treatment of MCH.

UR - http://www.scopus.com/inward/record.url?scp=84952307176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952307176&partnerID=8YFLogxK

U2 - 10.1159/000367992

DO - 10.1159/000367992

M3 - Article

C2 - 25531155

AN - SCOPUS:84925356492

VL - 83

SP - 94

EP - 101

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 2

ER -